These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32898246)

  • 41. Assessment of Temporary Warfarin Reversal in Patients With Left Ventricular Assist Devices: the KVAD Study.
    Sylvester KW; Grandoni J; Rhoten M; Coakley L; Matiello-Lyons E; Frankel K; Fortin B; Jolley K; Park HS; Freedman RY; Mehra MR; Givertz MM; Connors JM
    J Card Fail; 2024 Mar; ():. PubMed ID: 38521486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Three- versus four-factor prothrombin complex concentrate for the reversal of warfarin-induced bleeding.
    Holt T; Taylor S; Abraham P; Mcmillian W; Harris S; Curtis J; Elder T
    Int J Crit Illn Inj Sci; 2018; 8(1):36-40. PubMed ID: 29619338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing warfarin reversal--an ex vivo study.
    Gatt A; Riddell A; van Veen JJ; Kitchen S; Tuddenham EG; Makris M
    J Thromb Haemost; 2009 Jul; 7(7):1123-7. PubMed ID: 19575759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.
    Brekelmans MPA; Ginkel KV; Daams JG; Hutten BA; Middeldorp S; Coppens M
    J Thromb Thrombolysis; 2017 Jul; 44(1):118-129. PubMed ID: 28540468
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal.
    McMahon C; Halfpap J; Zhao Q; Bienvenida A; Rose AE
    Ann Pharmacother; 2021 Oct; 55(10):1230-1235. PubMed ID: 33522256
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emergent reversal of vitamin K antagonists: addressing all the factors.
    Martin DT; Barton CA; Dodgion C; Schreiber M
    Am J Surg; 2016 May; 211(5):919-25. PubMed ID: 27046797
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal.
    Baggs JH; Patanwala AE; Williams EM; Erstad BL
    Ann Pharmacother; 2012 Jan; 46(1):51-6. PubMed ID: 22190253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new kid on the block: Outcomes with Kcentra 1 year after approval.
    Berndtson AE; Huang WT; Box K; Kobayashi L; Godat LN; Smith AM; Weingarten D; Coimbra R
    J Trauma Acute Care Surg; 2015 Dec; 79(6):1004-8. PubMed ID: 26488322
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of four-factor prothrombin complex concentrate in the reversal of warfarin-induced and nonvitamin K antagonist-related coagulopathy.
    Young H; Holzmacher JL; Amdur R; Gondek S; Sarani B; Schroeder ME
    Blood Coagul Fibrinolysis; 2017 Oct; 28(7):564-569. PubMed ID: 28604569
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Hemostatic Outcomes in Patients Receiving Fixed-Dose vs. Weight-Based 4-Factor Prothrombin Complex Concentrate.
    Kim C; Cottingham L; Eberwein K; Komyathy K; Ratliff PD
    J Emerg Med; 2020 Jul; 59(1):25-32. PubMed ID: 32536491
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin.
    Chapman SA; Irwin ED; Beal AL; Kulinski NM; Hutson KE; Thorson MA
    Ann Pharmacother; 2011 Jul; 45(7-8):869-75. PubMed ID: 21775690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse Events Following International Normalized Ratio Reversal in Intracerebral Hemorrhage.
    Laible M; Jenetzky E; Beynon C; Müller OJ; Sander P; Schüler S; Purrucker J; Möhlenbruch M; Steiner T; Veltkamp R; Ringleb PA; Rizos T
    Cerebrovasc Dis; 2016; 42(5-6):446-454. PubMed ID: 27536779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prothrombin complex concentrate accelerates international normalized ratio reversal and diminishes the extension of intracranial hemorrhage in geriatric trauma patients.
    Edavettal M; Rogers A; Rogers F; Horst M; Leng W
    Am Surg; 2014 Apr; 80(4):372-6. PubMed ID: 24887668
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Four-Factor Prothrombin Complex Concentrate for Coagulopathy Reversal in Patients With Liver Disease.
    Huang WT; Cang WC; Derry KL; Lane JR; von Drygalski A
    Clin Appl Thromb Hemost; 2017 Nov; 23(8):1028-1035. PubMed ID: 27628534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices.
    Rimsans J; Levesque A; Lyons E; Sylvester K; Givertz MM; Mehra MR; Stewart GC; Connors JM
    J Thromb Thrombolysis; 2018 Aug; 46(2):180-185. PubMed ID: 29785470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.
    Zemrak W; Manuel F; Smith KE; Rolfe S; Hayes T; Trowbridge RL; Carlone B; Seder D
    J Thromb Thrombolysis; 2019 Feb; 47(2):263-271. PubMed ID: 30443817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Experience on using prothrombin complex concentrate in urgent warfarin reversal: an Iranian survey.
    Haghpanah S; Karimi M; Bordbar M; Kamfiroozi R; Asgharzadeh H
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):277-81. PubMed ID: 22734101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial.
    Steiner T; Poli S; Griebe M; Hüsing J; Hajda J; Freiberger A; Bendszus M; Bösel J; Christensen H; Dohmen C; Hennerici M; Kollmer J; Stetefeld H; Wartenberg KE; Weimar C; Hacke W; Veltkamp R
    Lancet Neurol; 2016 May; 15(6):566-73. PubMed ID: 27302126
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
    D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
    Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Coagulation Factor Plasma Levels Following Administration of a 4-Factor Prothrombin Complex Concentrate for Rapid Vitamin K Antagonist Reversal in Japanese Patients.
    Yasaka M; Brainsky A; Zhang P; Kushimoto S
    Curr Ther Res Clin Exp; 2018; 89():21-26. PubMed ID: 30224939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.